Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

↗ اشتراک‌گذاری

According to the BBC, the US Food and Drug Administration (FDA) has ordered manufacturers of GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, to add warnings about nonarteritic anterior ischemic optic neuropathy (NAION) to their labels. This disorder occurs when blood flow to the optic nerves is blocked, potentially causing sudden, painless, and permanent vision loss in one eye. The American Academy of Ophthalmology stated that while there appears to be an increased risk, a definitive cause-and-effect relationship has not been established. Novo Nordisk, the manufacturer of Wegovy, emphasized that patient safety is a priority but noted that the data does not establish a causal link. The FDA concluded after a review of reports and studies that there is an increased risk of rare NAION events in users of these drugs, though the exact reason for this association remains unknown.